Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Conversation
The Conversation
Steve Macfarlane, Head of Clinical Services, Dementia Support Australia, & Associate Professor of Psychiatry, Monash University

The TGA has approved donanemab for Alzheimer’s disease. How does this drug work and who will be able to access it?

Kateryna Kon/Shutterstock

This week, Australia’s Therapeutic Goods Administration (TGA) approved a drug called donanemab for people in the early stages of Alzheimer’s disease.

Donanemab has previously been approved in a number of other countries, including the United States.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.